Drug intelligence / Profile preview

letrozole + anlotinib hydrochloride

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Letrozole + anlotinib hydrochloride is a combination therapy under investigation for the treatment of certain cancers, notably platinum-resistant recurrent ovarian cancer. Letrozole is a nonsteroidal aromatase inhibitor that reduces estrogen production, thereby inhibiting the growth of hormone receptor–positive tumors. Anlotinib hydrochloride is a small-molecule multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. The combination aims to leverage both hormonal suppression (via letrozole) and antiangiogenic/antiproliferative effects (via anlotinib) to improve outcomes in difficult-to-treat cancers[1][2][3].

Other names: letrozole + anlotinib hydrochloride

Targets

CYP2C19 (Cytochrome P450 2C19)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR3 (Fibroblast growth factor receptor 3)CYP19A1 (Aromatase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)CYP2A6 (Cytochrome P450 2A6)

Beyond the preview

Go deeper on letrozole + anlotinib hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + anlotinib hydrochloride.

Explore the full profile